Oddo BHF - COP 30: a difficult balancing act between new commitments and the implementation of previous ones

Report

Oddo BHF

Emira Sagaama ...

Marc Lavaud

COP 30: a difficult balancing act between new commitments and the implementation of previous ones

07/11/2025 1 EN

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Emira Sagaama

Marc Lavaud

Other Reports from Oddo BHF

Michael B. Schäfer

Michael B. Schäfer

EMS-Chemie : Superior business model, but harvest is challenging when it rains

We are initiating coverage of EMS Chemie with a Neutral rating and a target price of CHF 560. The family-controlled and asset-light (superior ROCE of ~35%) Engineering Plastics pure play has undergone a major expansion capex phase, creating capacity to grow into. The currently challenging automotive market (60% of its end market) mutes the momentum needed to unlock our estimated CHF 95m (18% of CHF 539m EBIT 2024) incremental EBIT contribution in the short term, expected in full only in 2028 (CHF 638m, css CHF 637m). EMS currently trades at 19.6x EV/EBITDA 2026, a 13% discount compared to 8 ye...

11h / 49m 11h / 49m 1 EN

Martial Descoutures ... (+2)

Martial Descoutures
Oussema Denguir

Sandoz : Un positionnement unique au cœur des systèmes de santé sous contrainte

Nous initions Sandoz à Neutre avec un objectif de cours de 57 CHF. Sandoz est aujourd’hui l’un des leaders mondiaux des génériques complexes et biosimilaires, issu de la scission de Novartis en 2023. Dès sa première année pleine d’indépendance, le groupe a démontré la solidité de son modèle avec des ventes supérieures à 10 Md$ en 2024. Dans un environnement macroéconomique et réglementaire contraint, son portefeuille de 1 300 produits génériques et biosimilaires lui confère un profil défensif (génériques) boosté par la dynamique des biosimilaires (TMVA 24-28e des BPA core de 16%). Cependant, l...

11h / 49m 11h / 49m 1 FR

Martial Descoutures ... (+2)

Martial Descoutures
Oussema Denguir

Sandoz : A unique position at the heart of healthcare systems under pressure

We are initiating coverage of Sandoz with a Neutral rating and a target price of CHF 57. It is now one of the world leaders in complex generics and biosimilars, having been spun off from Novartis in 2023. In its first full year of independence, it has demonstrated the strength of its model, with revenues topping $ 10bn in 2024. In a constrained macroeconomic and regulatory environment, its portfolio of ~1,300 generic and biosimilar products gives it a defensive profile (generics) boosted by momentum from biosimilars (core EPS growth of 16% over 2024-28). But the current valuation already large...

11h / 49m 11h / 49m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

COP 30: a difficult balancing act between new commitments and the implementation of previous ones

EMS-Chemie : Superior business model, but harvest is challenging when it rains

Sandoz : Un positionnement unique au cœur des systèmes de santé sous contrainte

Sandoz : A unique position at the heart of healthcare systems under pressure

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe